#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Gaucher's disease type III Follicle centre lymphoma follicular grade I, II – III Liposarcoma Epilepsy with myoclonic-atonic seizures Loeys-Dietz syndrome Idiopathic pulmonary fibrosis Cutaneous T-cell lymphoma refractory Acquired C1 inhibitor deficiency Advanced systemic mastocytosis Chronic hepatitis B Lupus nephritis Antiphospholipid antibodies Leukaemia Gastrointestinal stromal tumour Marfan's syndrome More trials…

    Learn about Rare Diseases

    Hereditary ataxia – Trials in Disease Mast cell activation syndrome – Treatment Atypical teratoid/rhabdoid tumour of CNS – Treatment Nephrotic syndrome – Diagnostics Retinitis pigmentosa – Treatment Chondrosarcoma metastatic – Diagnostics Brain stem glioma – Treatment Progressive supranuclear palsy – Basic Information Ewing’s sarcoma – Diagnostics Splenic marginal zone lymphoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Glpg3667 Fumarate SPY002 Trimetazidine Dihydrochloride Voriconazole Clebopride Hydrogen Maleate RNMB1 Pembrolizumab L-PHENYLALANINE Milnacipran Hydrochloride Zipalertinib Sodium Citrate Alectinib Umeclidinium Bromide Folinic Acid Pimecrolimus Pelacarsen Oxcarbazepine Ganirelix Clobetasol Bosutinib More therapies…

    Learn about Your Condition

    Vitiligo Behcet's syndrome Delirium Postoperative delirium Squamous cell carcinoma Migraine with aura Medulloblastoma recurrent Major depression Non-Hodgkin's lymphoma Pemphigoid Periodontitis Metastases to liver Prodromal Alzheimer's disease Prostate cancer Synovial sarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Dermatitis atopic

  • Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Adults with Moderate to Severe Atopic Dermatitis (Phase 2 Study)

    Not yet recruiting

    2 1
    Bulgaria Czechia Germany Italy Poland

  • A Phase 2b Study Evaluating the Efficacy and Safety of ENV-294 in Adults with Moderate-to-Severe Atopic Dermatitis

    Not yet recruiting

    2 1
    Czechia Germany Poland Spain

  • Pharmacokinetics, Safety and Efficacy of Nemolizumab in Infants 6–23 Months with Moderate-to-Severe Atopic Dermatitis

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Nemolizumab
    Poland

  • Phase 2b Randomized Double‑Blind Study of Oral PF‑08049820 in Adults with Moderate to Severe Atopic Dermatitis

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Bulgaria Czechia France Germany Poland

  • A Study of Lebrikizumab for Adults and Adolescents with Moderate to Severe Atopic Dermatitis to Evaluate Effects on Eczema and Skin Barrier Function

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Lebrikizumab
    Sweden

  • Testing GIA632 compared to placebo in adults with moderate to severe atopic dermatitis to measure effectiveness and safety

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Bulgaria Czechia France Germany Poland
Previous Page
1 2 3 4 5 … 15
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!